Last 48 quarters of trend data
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.52 | — | — | — | — | — | — | — | — | — | 3.38 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.29 | 0.74 | 0.90 | 1.20 | 1.29 | 1.72 | 0.99 | 0.57 | 77.91 | 1.21 | 0.43 | 1.63 | 0.99 | 0.64 | 0.82 | 0.71 | 0.76 | 1.20 | 0.74 | 0.89 | 0.98 |
| — | -57.0% | -9.1% | +111.2% | -98.3% | +42.5% | +131.0% | -65.1% | +7783.6% | +87.6% | -47.2% | +130.5% | +30.7% | -46.4% | +10.7% | -21.1% | -23.0% | -9.2% | -58.3% | +3.9% | +208.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.7% | -17.6% | -13.1% | -14.5% | -16.1% | -12.7% | -41.0% | -17.1% | -17.7% | -15.7% | 3.3% | 23.2% | -14.3% | -15.3% | -13.8% | -11.2% | -9.0% | -9.7% | -8.5% | -7.1% | -5.4% |
| — | -38.4% | +68.2% | +15.4% | +9.0% | +18.9% | -1359.6% | -173.9% | -23.6% | -2.5% | +123.7% | +306.1% | -59.3% | -57.9% | -62.1% | -57.6% | -65.2% | -176.3% | -361.8% | -278.0% | -20.6% | |
| ROA | -65.9% | -10.5% | -8.1% | -9.1% | -10.1% | -8.2% | -32.0% | -15.7% | -14.5% | -12.0% | 2.5% | 16.3% | -12.9% | -13.9% | -12.7% | -10.7% | -8.7% | -9.3% | -8.2% | -6.9% | -5.2% |
| — | -29.0% | +74.7% | +41.9% | +30.2% | +31.8% | -1366.7% | -196.2% | -12.2% | +13.8% | +119.9% | +252.0% | -49.1% | -48.8% | -54.9% | -56.2% | -65.2% | -170.8% | -352.1% | -268.1% | -19.8% | |
| ROIC | — | — | — | — | — | — | — | -134.5% | -127.1% | — | — | — | -117.5% | -176.6% | -157.2% | -92.1% | -61.7% | -70.3% | -61.0% | -55.3% | -46.1% |
| — | — | — | — | — | — | — | — | -8.2% | — | — | — | -90.3% | -151.2% | -157.6% | -66.4% | -33.9% | -19.2% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -34.2% | -14.8% | -15.3% | -15.0% | -70.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.23 | 1.91 | 2.08 | 2.19 | 2.23 | 2.27 | 2.43 | 9.08 | 11.62 | 3.55 | 4.07 | 1.74 | 9.13 | 8.62 | 9.75 | 14.02 | 29.91 | 22.06 | 23.41 | 32.73 | 19.51 |
| — | -15.8% | -14.1% | -75.8% | -80.8% | -36.2% | -40.4% | +422.4% | +27.2% | -58.8% | -58.3% | -87.6% | -69.5% | -60.9% | -58.3% | -57.2% | +53.3% | -44.6% | -61.2% | -69.4% | -61.3% | |
| Quick Ratio | 2.23 | 1.91 | 2.08 | 2.19 | 2.23 | 2.27 | 2.43 | 9.08 | 11.62 | 3.55 | 4.07 | 1.74 | 9.13 | 8.62 | 9.75 | 14.02 | 29.91 | 22.06 | 23.41 | 32.73 | 19.51 |
| — | -15.8% | -14.1% | -75.8% | -80.8% | -36.2% | -40.4% | +422.4% | +27.2% | -58.8% | -58.3% | -87.6% | -69.5% | -60.9% | -58.3% | -57.2% | +53.3% | -44.6% | -61.2% | -69.4% | -61.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FLNA stock.
Filana Therapeutics, Inc.'s current P/E is -0.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Filana Therapeutics, Inc.'s business trajectory between earnings reports.